Background: In popular media and on Internet, the neuropeptide oxytocin is often advertised as a miracle drug that cures all types of disorders, reduces stress, saves marriages, all conveniently with a nasal spray. Here we will present the effects of intranasal oxytocin on brain function in recently traumatized individuals and patients with posttraumatic stress disorder (PTSD) and discuss clinical implications and further research. PTSD is characterized by exaggerated fear responses to threat and traumarelated stimuli, reflected in altered neural salience processing and emotion regulation . In addition, many PTSD patients report anhedonia, emotional numbing, and social detachment, reflected in decreased reward sensitivity (Nawijn et al., 2015) . Interestingly, dysregulations in these domains also appear to be associated with increased PTSD risk upon trauma exposure and treatment non-response. Currently, there still is a high need for development of effective preventive interventions for PTSD, that can be administered early after trauma, as well as a need for novel adjuvant interventions that augment treatment response to evidence-based psychotherapy for PTSD (i.e., medication-enhanced psychotherapy [MEP]) (see also Hendriks & De Kleine, 2015) .
Conclusions: Combined, our findings on the effects of oxytocin administration on neural salience processing and emotion regulation indicate that a single oxytocin administration has differential effects in (recently) traumatized individuals and PTSD patients. This is in line with more recent literature on differential effects of oxytocin administration depending on interpersonal differences and (the interpretation of) the salience of contextual cues (Bartz, Zaki, Bolger, & Ochsner, 2011; Olff et al., 2013) . The observed effects of oxytocin administration in our recently traumatized population are contrary to our initial hypothesis, suggesting that caution is warranted regarding administration of oxytocin in recently traumatized individuals. However, for various reasons, it may be expected that repeated oxytocin administration has different effects than a single administration (for review, see Macdonald & Feifel, 2013) . Our randomized controlled trial on the effects of a 1-week oxytocin treatment regimen on PTSD prevention, which is currently well underway, will shed more light on the long-term clinical effects of oxytocin administration in recently traumatized individuals.
Our findings on the neural effects of a single oxytocin administration in PTSD patients are in line with our hypotheses. Thus, oxytocin is not a miracle panacea, but our results do support the notion that intranasal oxytocin administration is a promising candidate for augmentation of PTSD treatment response. As a next step, the potential of intranasal oxytocin administration as an adjunctive agent during psychotherapy for PTSD, such as before exposure-based therapies, should be further investigated in a clinical setting, preferably in a randomized placebo-controlled trial.
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